Skip to main
NTHI

NTHI Stock Forecast & Price Target

NTHI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeOnc Technologies Hldgs is a biopharmaceutical company with a promising focus on developing targeted treatments for difficult-to-treat brain tumors. Their financials have improved, and their promising lead drugs, NEO100 and NEO212, coupled with their innovative drug delivery methods, give them a bullish outlook for future success. Along with favorable safety profiles and potential for treating anemia and drug resistance, NeOnc Technologies Hldgs faces typical risks and is valued through a DCF analysis for future growth.

Bears say

NeOnc Technologies Hldgs is a clinical-stage biopharmaceutical company that is developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system (CNS) diseases. While their lead product candidates, NEO100 and NEO212, show promise in treating glioblastoma and other types of brain cancer, there are concerns regarding regulatory scrutiny and the company's ability to successfully develop and commercialize these products. Additionally, the company's financials and stock performance have been lackluster, making it a risky investment at this time.

NTHI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neonc Technologies Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neonc Technologies Holdings Inc (NTHI) Forecast

Analysts have given NTHI a Strong Buy based on their latest research and market trends.

According to 3 analysts, NTHI has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neonc Technologies Holdings Inc (NTHI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.